Elucidating Compound Mechanism of Action by Network Perturbation Analysis
Open accessAbstract
Genome-wide identification of the mechanism of action (MoA) of small-molecule compounds characterizing their targets, effectors, and activity modulators represents a highly relevant yet elusive goal, with critical implications for assessment of compound efficacy and toxicity. Current approaches are labor intensive and mostly limited to elucidating high-affinity binding target proteins. We introduce a regulatory network-based approach that elucidates genome-wide MoA proteins based on the assessment of the global dysregulation of their molecular interactions following compound perturbation. Analysis of cellular perturbation profiles identified established MoA proteins for 70% of the tested compounds and elucidated novel proteins that were experimentally validated. Finally, unknown-MoA compound analysis revealed altretamine, an anticancer drug, as an inhibitor of glutathione peroxidase 4 lipid repair activity, which was experimentally confirmed, thus revealing unexpected similarity to the activity of sulfasalazine. This suggests that regulatory network analysis can provide valuable mechanistic insight into the elucidation of small-molecule MoA and compound similarity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Altretamine has been identified as a potential inhibitor of GPX4 by a regulatory network genome-wide system strategy.
“altretamine (an FDA-approved alkylating agent) has been recently identified as a potential inhibitor of GPX4 by a regulatory network genome-wide system strategy [558].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [558]
The antineoplastic effects of sorafenib and altretamine may partially stem from activation of ferroptosis.
“Thus, the antineoplastic effects of sorafenib and altretamine may partially stem from the activation of ferroptosis.”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [558]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 59 · Cited by 351
- Authors
- Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez Martínez, M., López, G., Mattioli, M., Realubit, R., Karan, C., Stockwell, B. R., Bansal, M., & Califano, A.
- Affiliations
- Columbia University (US)
- Italian Institute of Technology (IT)
- Howard Hughes Medical Institute (US)
- Herbert Irving Comprehensive Cancer Center (US)
- Corresponding author
- Bansal, Mukesh
- Califano, Andrea
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 162
- Issue
- 2
- Pages
- 441-451
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4506491
- OpenAlex
- W1535350845
- Cited by
- 351
- References
- 59
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 41 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 29 · 2019: 32 · 2018: 26 · 2017: 22 · 2016: 26 · 2015: 6
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (1s10od012351-01)
- National Heart, Lung, and Blood Institute (U01HL111566)
- National Cancer Institute (U54CA121852, R35CA209896, U01CA164184, R01CA097061, U01CA168426, R01CA161061)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Keywords
- mechanism of action, small molecules, protein-protein interaction network, altretamine, GPX4, sulfasalazine, molecular similarity, drug target identification, drug toxicity
- MeSH terms
- Algorithms, Antineoplastic Agents, Epistasis, Genetic, Neoplasms, Small Molecule Libraries, Genome-Wide Association Study, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review